Plasma Cancer Therapy In Dermatology

Publication date: February 2018 Source:Clinical Plasma Medicine, Volume 9, Supplement Author(s): Georg Daeschlein, Claudia Sicher, Sebastian von Podewils, Rico Rutkowski, Michael Jünger Main topics in cancer treatment in dermatology are melanoma (MM), basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and metastatic skin tumors. Thereof stage IV MM because of fatal outcome is uf utmost importance. Despite some substantial therapeutic progress now in this entity by immunologic treatments alternatives are warranted when disease is progressing under therapy or the tumor basically appears refractory. National guidelines currently recommend ipilumumab, vemurafenib, dabrafenib, and high-dose IL-2 as first line agents for Stage IV melanoma but no data exists to guide management of cutaneous and subcutaneous metastases which are very common. Therapeutic options include intralesional electrochemotherapy and Bacillus Calmette-Guérin, isolated limb perfusion/infusion, interferon-α, topical imiquimod, cryotherapy, radiation, interferon therapy, and intratumoral interleukin-2 injections. Recent developments include anti-programmed cell death 1 receptor agents (PD-1, nivolumab and pembrolizumab), anti-programmed death-ligand 1 agents, and oncolytic vaccines (talimogene laherparepevec), adoptive T cell therapy and dendritic cell vaccines. Regarding BCC and SCC mainly the aggressive variants are of interest for new therapies. A third entity are metastatic tumors of different...
Source: Clinical Plasma Medicine - Category: Research Source Type: research